Tag : OSA

Weight loss is commonly recommended for treating obstructive sleep apnea (OSA) in those with obesity. However, achieving and maintaining this weight loss is often difficult without bariatric surgery, and no approved anti-obesity medications have proven effective for OSA management. Recently, the United States Food and Drug Administration (US FDA) approved tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, as the first pharmacological treatment for moderate-to-severe OSA in adults with obesity. This approval, based on the results of the phase 3 SURMOUNT-OSA trial, introduces a new treatment option for sleep medicine, providing an alternative to traditional management methods such as positive airway pressure (PAP) therapy.